Royalty Pharma (RPRX) Business News Dec. 29, 2025, 21:40 UTC Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones Full text
Register to leave comments News bot Dec. 30, 2025, 7:03 a.m. 📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical